Imigran Novum

Sumatriptan, the active ingredient in Imigran Novum, is a selective serotonin (5‑HT1B/1D) receptor agonist presented as an oral tablet for oral use. It is employed for the acute treatment of migraine attacks in adults.

GNH USA supplies Imigran Novum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imigran Novum belongs to the triptan class and is used to treat migraine‑related disorders. - Migraine: aborts acute migraine attacks and relieves associated headache pain. - Cluster headache: provides relief of acute cluster headache episodes. - Acute headache of other vascular origin: may be used to treat short‑lasting vascular headaches when prescribed.

Common Side Effects: - Chest discomfort or tightness - Tingling or numbness in the face or extremities - Nausea or upset stomach - Dizziness or light‑headedness - Fatigue or weakness - Dry mouth

Serious or Rare Side Effects: - Coronary vasospasm or myocardial infarction - Serotonin syndrome, especially with other serotonergic drugs - Severe allergic reactions (anaphylaxis, angioedema) - Stroke or transient ischemic attack - Hypertension or hypertensive crisis - Severe arrhythmias

Before using Imigran Novum, consider the following precautions: - Cardiovascular disease: avoid if you have coronary artery disease, uncontrolled hypertension, or a history of myocardial infarction. - History of stroke or transient ischemic attack: use only under strict medical supervision. - Concomitant serotonergic agents: assess risk of serotonin syndrome when combined with SSRIs, SNRIs, or MAO inhibitors. - Pregnancy and lactation: safety not established; discuss risks with a healthcare professional. - Age considerations: use caution in elderly patients due to increased cardiovascular risk. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Sumatriptan may interact with several drug classes. Major Interactions (Avoid): - MAO inhibitors: increase risk of serotonin syndrome. - Other triptans or ergot alkaloids: may cause excessive vasoconstriction. - SSRIs, SNRIs, or other serotonergic agents: heightened serotonin toxicity. - Certain antihypertensives (e.g., ergot derivatives): additive vasoconstrictive effect. - Monoamine oxidase inhibitors (both reversible and irreversible).

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise sumatriptan plasma levels. - Oral contraceptives: possible reduced efficacy of migraine relief. - Antihistamines or sedatives: may enhance dizziness or drowsiness. - Alcohol: can increase the likelihood of side effects. - Herbal supplements (e.g., St. John’s wort): potential serotonergic interaction.